HER2DX®️, The First Genomic Tool For Patients With HER2+ Breast Cancer
Time: 12:00 pm
day: Day One
Details:
- HER2DX®️ development, validation and clinical utility
- HER2DX®️ IGG/immune signature as a key component of the test
- Delving into future directions
